38 results
SC TO-C
EX-99.1
eMed, LLC
30 Jan 24
Information about tender offer
10:11am
will be able to continue to pursue the existing mission of the Company.”
The transaction is subject to the tender of a majority of Science 37’s … not assume any obligation to update these estimates.
About Science 37:
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical
SC14D9C
EX-99.2
SNCE
Science 37 Holdings Inc
29 Jan 24
Written communication relating to third party tender offer
4:10pm
to clinical trials for patients and provide opportunities for employees.
eMed believes in our mission and the market opportunity in front of us … that will streamline our participant experience, and capital to expand our capabilities and ensure long-term sustainability.
Maintaining the Mission
SC14D9C
EX-99.6
SNCE
Science 37 Holdings Inc
29 Jan 24
Written communication relating to third party tender offer
4:10pm
mission and its market opportunity, and is committed to investing in the combined company’s future.
We believe the combined power of eMed’s consumer … in ownership, not a shift in our commitment to our mission and delivering outstanding clinical trial services.
Science 37 remains resolute in its
SC14D9C
EX-99.5
SNCE
Science 37 Holdings Inc
29 Jan 24
Written communication relating to third party tender offer
4:10pm
mission and its market opportunity, and is committed to investing in the combined company’s future.
We believe the combined power of eMed’s consumer … forward in delivering our mission of universal access to patients for our customers, employees, and shareholders.
With the support of eMed, we expect
8-K
EX-99.1
SNCE
Science 37 Holdings Inc
29 Jan 24
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
7:35am
will be able to continue to pursue the existing mission of the Company.”
The transaction is subject to the tender of a majority of Science 37’s … not assume any obligation to update these estimates.
About Science 37:
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical
8-K
EX-99.1
kfi9 ik0g6a6
5 Dec 23
Material Modifications to Rights of Security Holders
7:03am
8-K
EX-99.1
n8btfgbv
7 Nov 23
Science 37 Reports Third Quarter 2023 Financial Results
6:02am
8-K
EX-99.1
r385e8kr wrhxco9s2lf
8 Aug 23
Science 37 Reports Second Quarter 2023 Financial Results
6:02am
8-K
EX-99.1
spuna atx
15 May 23
Science 37 Reports First Quarter 2023 Financial Results
6:04am
8-K
EX-99.1
z3ztm5a
11 Apr 23
Science 37 Unveils Three Global Centers of Excellence to Drive Efficiency, Speed and Quality
4:08pm
8-K
EX-99.1
qbmdsd99cne26px85pza
10 Nov 22
Science 37 Reports Third Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
55s5ejzsxor
5 Oct 22
Science 37 appoints Paul von Autenried to its Board of Directors
4:17pm
8-K
EX-99.1
7ft 7lz8ftnc3tu
12 Sep 22
Science 37 Names Industry Veteran Michael Shipton as Chief Commercial Officer
7:59am
8-K
EX-99.1
kujxwaguddfuug67xok0
11 Aug 22
Science 37 Reports Second Quarter 2022 Financial Results
6:01am
8-K
EX-99.1
5cputb4o3ml
9 May 22
Science 37 Reports First Quarter 2022 Financial Results
12:00am
424B3
3ymz0
4 May 22
Prospectus supplement
12:43pm
424B3
fqfc76helobr
27 Apr 22
Prospectus supplement
4:19pm
POS AM
sjxfdyrsfo600w4w
8 Apr 22
Prospectus update (post-effective amendment)
4:41pm
424B3
mf5s9vixuoxoo 12dm
22 Mar 22
Prospectus supplement
7:28am